Skip to main content
| News

Resistell receives high-level EU grant

10.07.2020

Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.

Resistell AG is one of 70 companies selected for funding in the most recent financing round within the framework of the EIC Accelerator Pilot program (previously known as the SME instrument) established by the European Innovation Council. In total, 4,000 applications were submitted, more than double the usual amount. The startup will receive up to 2.5 million euros for the clinical validation of its antibiotic susceptibility test. Moreover, the EIC Accelerator is offering blended financing in the form of an optional investment in equity in addition to the grant.

This is the world’s fastest phenotypic antibiotic susceptibility test, reducing the duration needed for such a test from several hours or even days to less than two hours. It is set to help conquer one of the largest challenges in the healthcare sector: antimicrobial resistance (AMR). A press release outlines how, in many countries, suspected COVID-19 patients have been treated with antimicrobial therapies as a precaution in hospital. However, the excessive use of these powerful medicines can trigger the development of multi-drug resistance, the press release states further. There is therefore an urgent need for global action “to prevent COVID-19 from casting a long shadow over antimicrobial resistance”.

The grant and equity participation from the EIC Accelerator will co-finance the final development stage of the Resistell device and disposable articles in addition to the multicenter performance evaluation study. “This funding will help us mitigate the financial and clinical risks that have emerged because of COVID-19”, states Danuta Cichocka, CEO of Resistell.

“Thanks to this project, we will be able to carry out clinical validation in at least three different hospitals in Switzerland, Germany and Denmark”, she explains further. This will help not only to accelerate and facilitate market entry, but will also ensure continuity with regard to the performance evaluation study under pandemic conditions.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
1 2 3 60

Do you have a question? We'd like to hear from you.